Factor XIa inhibitor versus DOAC in patients with AF at high stroke risk
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- ESC Congress 2024
Continuation or interruption of OAC during TAVI?
Dirk Jan van Ginkel, MD
- ESC Congress 2024
Beneficial effects of MRAs in HF across the LVEF spectrum
Pardeep Jhund, MD, PhD
- ESC Congress 2024
Effects of empaglifozin on kidney outcomes after acute MI
Deepak Bhatt, MD
- ESC Congress 2024
Predicting 30-year CV outcomes in women
Paul Ridker, MD